Latest Posts
Bahraini foodtech startup Calo has expanded into the UK with the acquisition of UK-based meal delivery brands Fresh Fitness Food and Detox Kitchen. This…
Built in the UAE, Munsit sets a new global standard for Arabic speech recognition, powering seamless transcription across private and public services…
April 2025 – The Innovative Startups and SMEs Fund (ISSF) – the largest investment fund of its kind in Jordan has announced a USD 3 million…
Umm Al Quwain, UAE – In an inspiring tribute to Earth Day 2025, the Emirates Environmental Group (EEG), in strong and strategic collaboration…
The fifth edition of the A.R.M. Holding Children’s Programme launches today in schools across the UAE, timed to coincide with World Creativity and…
Don't Miss
Featured Topics
More Posts
Get ready for an all-new ladies’ night curated by the multi-award-winning Solutions Group, bringing together…
Oxford Business Group, in collaboration with the Sharjah Commerce and Tourism Development Authority (SCTDA), presents…
In a groundbreaking collaboration with Al Etihad Payments (AEP), a subsidiary of the Central Bank…
Abu Dhabi, United Arab Emirates, July 2024: Abu Dhabi Motors, the official importer of BMW Group…
The African Development Bank (www.AfDB.org) has appointed Dr Babatunde Samson Omotosho, an economist and statistician, as…
As the trend towards youthful and firm skin continues to grow, various aesthetic procedures to…
Follow Us
Must Read
Timely Detection of Partial Anomalous Pulmonary Venous Drainage (PAPVD) Enables Early, Life-Protecting Care Abu Dhabi, UAE, 24 March 2026 – SEHA, a subsidiary of PureHealth, the largest healthcare group in the Middle East, announced the successful early diagnosis of a rare congenital heart condition, Partial Anomalous Pulmonary Venous Drainage (PAPVD), in a full-term newborn admitted to SEHA’s Corniche Hospital’s Neonatal Intensive Care Unit (NICU) with respiratory distress. On the second day of life, the newborn initially presented with breathing difficulties, which prompted a comprehensive clinical assessment by the hos